This study aims to address these gaps by providing a comprehensive analysis of FAM210B's role in HCC through various methods, including pan‐cancer expression analysis, subcellular localization studies, functional assays in HCC cell lines and assessments of the immune microenvironment and drug sensitivity. The gene discussed is MIMS2; the disease is hepatocellular carcinoma.